In recent years, the genetic testing industry is in a stage of rapid development, and major changes have occurred in the industry. Among them, the increase in the number of players entering the genetic testing industry represents a certain degree of vigorous development of the industry. According to the incomplete statistics of Gene Hui, in the domestic genetic industry in 2017, a total of 55 companies were financing, with a total financing of 9.013 billion yuan, a year-on-year increase of 60%.
In the frontier forum for the development of genetic testing, Tsinghua University School of Pharmacy Bai Jingwei, Rendong Medical CEO Jin Ge, Huidu Medical CEO Jia Shidong, first gene CEO Tang Yuanhua and Dachen Venture Capital Managing Director Xu Yuanping around the development trend of genetic testing The issue was discussed in depth.
Starting from the technical aspect of genetic testing, Bai Jingwei said at the conference that genetic testing technology is developing from second-generation sequencing to third- and fourth-generation sequencing.
In fact, the second generation of sequencing in the past is like "C-debut" in the field of genetic testing. In Bai Weiwei's view, the advantages of second-generation sequencing are mainly high throughput and high accuracy. Simply put, this technique randomly cuts DNA into innumerable small fragments, so second-generation sequencing is not just measuring one fragment at a time, but analyzing millions of fragments.
However, it is precisely based on such technical advantages that the sequencing read length is short, and the long sequencing time naturally becomes its disadvantage. In fact, the biochemical reaction rate of the second-generation sequencing technology itself is difficult to reach 100%. Countless segments of short sequencing read lengths are like a huge square matrix. When it is impossible to ensure that everyone has the same pace, it is difficult to make the square matrix maintain its original formation after the full course. Based on this logic, Bai Jingwei believes that it is difficult to ensure that efficiency has become a core issue facing the second generation of sequencing technology.
It is also because of this deficiency that three or four generations of sequencing technology have been derived. Bai Jingwei introduced that the sequencing technology developed to this stage is characterized by single-molecule sequential sequencing. Its biggest advantage is its long read length, faster sequencing speed and less reagent usage. From a technical perspective, the new generation of sequencing technology still needs to face various challenges. In addition, Bai Jingwei also believes that higher integration, higher throughput and high signal-to-noise ratio sensor will be the future single. The research direction of molecular sequencing technology.
From the perspective of business development logic, Jin Ge believes that technology is only a means of transition, and joint treatment will become a new trend in the future.
According to the "2018-2023 Global Precision Medical Market Prospects Survey and Investment Opportunity Research Report", from 2016 to 2020, the global precision medical market will grow at a rate of 15% per year. It is expected that the global precision medical market will be broken in 2020. Billions, reaching $105 billion. It is expected that by 2020, the precision medical company with early disease screening and accompanying treatment will become the mainstream of China's cancer diagnosis and treatment market.
Therefore, some people say that genetic testing has not entered the golden decade, and the boom in this field is also reflected in the continuous integration of genetic testing with other disciplines. However, Jin Ge said that rather than the technology represented by genetic testing and immunotherapy, she is more willing to believe that the future development trend in this field is joint therapy.
Because at the end of the day, all technologies need to return to the essence of business and medical care. Jin Ge believes that the clinical requirements are high reproducibility, high detection rate and practicality. For the patient, the ultimate service of the medical service, the enterprise should provide a better solution. Based on this, there is a natural intersection between genetic testing, bioinformatics engineering, and new drug research and development. It is precisely because of this that Jin Ge believes that more interdisciplines will be derived in the future, and joint treatment will be the main development in the future. trend.
With the continuous development of the genetic testing industry and the increasingly fierce competition in the industry, how to establish their own barriers has become a key link. From the perspective of business development logic, Jin Ge believes that it is unrealistic for enterprises to lay out and establish barriers in advance in data, team, system and other aspects. Only by combining all the above factors can we form a real barrier. .
In the view of Golden Dove, the trend of all major technologies is not a trend, because the new technologies advocated in the constantly changing new technology wave will always be overwhelmed. Therefore, technology as a means is just a way to help the industry complete the transition.
Lysine Aspirin,Indomethacin Capsules,Analgesic & Antipyretic,Diclofenac Injection Uses
NINGBO VOICE BIOCHEMIC CO. LTD , https://www.medicine-voice.com